General Archive
-
News releasesNew AI tool aims to detect early signs of dementia during routine eye tests
Data scientists and clinical researchers are working with high street opticians for the first time to develop a digital tool…
-
News releasesTwo major UK decisions announced on use of Alzheimer’s drug, lecanemab
Today, two major decisions have been made on lecanemab (Leqembi®) – the Alzheimer’s drug that we helped humanise, which slows the…
-
NEURii: Transforming care for people living with dementia throughUK-based collaboration
NEURii: Transforming care for people living with dementia through UK-based collaboration In partnership with Eisai, Gates Ventures, Health Data Research…
-
UKRI: A £30 million partnership for the development of new dementia treatments
UK DRI: A £30 million partnership for the development of new dementia treatments Our partnership with the UK Dementia Research…
-
News releasesLifeArc appoints new chair for neurodegeneration efforts
Today, we’re pleased to announce the appointment of Professor Roger Barker as Chair of our neurodegeneration efforts. Professor Barker is…
-
News releasesSeven neurodegeneration research projects receive £14.5m from LifeArc-UKDRI partnership
The first projects to be funded through LifeArc’s £30 million strategic partnership with the UK Dementia Research Institute (UKDRI) have…
-
News releasesLifeArc helps fund new research institute to accelerate the search for a cure for MND
A new research institute to accelerate the search for a cure for motor neuron disease (MND, also known as ALS),…
-
Articles
New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
-
News releases
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures
-
ArticlesHow LifeArc’s Neurodegeneration Translational Challenge is leading the charge against Motor Neurone Disease
June 21st is Global MND Awareness Day, a day to raise worldwide awareness of MND (Motor Neurone Disease) and to…
-
ArticlesAlzheimer’s drug lecanemab approved by US regulator
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the…
-
ArticlesLifeArc plays key role in discovery of new Alzheimer’s treatment
LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people…